Loading
A phase 1/2 trial of TGX-007 in glioma & glioblastoma, run by Trogenix ltd, now recruiting.
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma is a phase 1/2 interventional study registered as NCT07346144 by Trogenix ltd, with 68 participants planned, started 2026-04-21 and due to reach its primary completion in 2030-03. Interventions recorded: TGX-007 and Valaciclovir.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/